Objective: To evaluate the impact of new national drug pricing policy (NDPP) 2018 on the access to medicines in terms of prices, availability, and affordability. Design: Two cross-sectional surveys

DataONE2020-09-08 更新60

Differences in quality use of medicines between countries that did versus did not report implementation of specific medicine policies.

药品政策评估

跨国合理用药比较

The table presents the weighted mean (and 95% confidence interval) of differences (in percent) across ten selected measures of QUM between countries that did versus did not report implementation of sp

Figshare2015-12-02 更新40

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders

药品政策评估

健康技术评估

Objectives This study aimed to identify the barriers and facilitators to improve the use of health technology assessment (HTA) for the selection of medicines listed in the e-Catalogue and the national

NIAID Data Ecosystem60

Essential Medicines in a High Income Country: Essential to Whom?

药品政策评估

供应链管理

Objective To explore the perspectives of a diverse group of stakeholders engaged in medicines decision making around what constitutes an “essential” medicine, and how the Essential Medicines List (EML

NIAID Data Ecosystem50

Stakeholder Comments on the Aim and Function of an EML in Australia.

资源简介：

相关数据集